Clinical aspects and management of levodopa-induced dyskinesia

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Tambasco, Nicola ^a   Simoni, Simone ^a   Marsili, Erica ^a   Sacchini, Elisa ^a   Murasecco, Donatella ^a   Cardaioli, Gabriela ^a   Rossi, Aroldo ^a   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

ADJUVANT THERAPY; BRAIN DEPTH STIMULATION; CHRONIC DRUG ADMINISTRATION; DENERVATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; MONOTHERAPY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SUBSTANTIA NIGRA;

EID: 84863663078     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/745947     Document Type: Review

References (124)

1. Calabresi P., Filippo M. D., Ghiglieri V., Tambasco N., Picconi B., Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap The Lancet Neurology 2010 9 11 1106 1117
2. Stocchi F., Tagliati M., Olanow C. W., Treatment of levodopa-induced motor complications Movement Disorders 2008 23 supplement 3 S599 S612
3. Tambasco N., Belcastro V., Gallina A., Castrioto A., Calabresi P., Rossi A., Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease Journal of Neurology 2011 2296 2299
4. Nutt J. G., Pharmacokinetics and pharmacodynamics of levodopa Movement Disorders 2008 23 supplement 3 S580 S584
5. Hauser R. A., McDermott M. P., Messing S., Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease Archives of Neurology 2006 63 12 1756 1760 (Pubitemid 44925085)
6. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Masso J. F. M., Montastruc J. L., The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study CNS Drugs 2004 18 11 733 746 (Pubitemid 39243565)
7. The Parkinson Study Group, Pramipexole vs levodopa as initial treatment for Parkinson Disease: a 4-year randomized controlled trial Archives of Neurology 2004 61 7 1044 1053
8. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E., A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa The New England Journal of Medicine 2000 342 20 1484 1491 (Pubitemid 30318272)
9. Kostic V., Przedborski S., Flaster E., Sternic N., Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease Neurology 1991 41 2 I 202 205
10. Schrag A., Hovris A., Morley D., Quinn N., Jahanshahi M., Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences Movement Disorders 2003 18 11 1250 1256 (Pubitemid 38263307)
11. The Parkinson Study Group, Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa Annals of Neurology 1996 39 1 29 36
12. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E., Abdalla M., Harmant J., Jacquy J., King D., Martin W., Destee A., Durif F., Aharon-Peretz J., Reches A., Bergamasco B., Bracco F., Frattolla L., Nordera P., Pezzoli G., Scarlato G., Stocchi F., Hovestadt A., Abbott R., Bakheit M., Boddie G., Brooks D. J., Clarke C. E., Corston R., Hawkes C., Kennard C., Loizou L., McLellan L., Park D., Sagar H., Spokes E., Ward C., Wroe S. V., Development of dyskinesias in a 5-year trial and ropinirole and L-dopa Movement Disorders 2006 21 11 1844 1850 (Pubitemid 44848929)
13. Fabbrini G., Brotchie J. M., Grandas F., Nomoto M., Goetz C. G., Levodopa-induced dyskinesias Movement Disorders 2007 22 10 1379 1389 (Pubitemid 47280623)
14. Schrag A., Quinn N., Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study Brain 2000 123 11 2297 2305
15. Schrag A., Schott J. M., Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism The Lancet Neurology 2006 5 4 355 363
16. Kumar N., Van Gerpen J. A., Bower J. H., Ahlskog J. E., Levodopa-dyskinesia incidence by age of Parkinson's disease onset Movement Disorders 2005 20 3 342 344 (Pubitemid 40613295)
17. Lyons K. E., Hubble J. P., Trster A. I., Pahwa R., Koller W. C., Gender differences in Parkinson's disease Clinical Neuropharmacology 1998 21 2 118 121 (Pubitemid 28152962)
18. Zappia M., Annesi G., Nicoletti G., Arabia G., Annesi F., Messina D., Pugliese P., Spadafora P., Tarantino P., Carrideo S., Civitelli D., De Marco E. V., Cir-Candiano I. C., Gambardella A., Quattrone A., Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study Archives of Neurology 2005 62 4 601 605 (Pubitemid 40489893)
19. Gilgun-Sherki Y., Djaldetti R., Melamed E., Offen D., Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease Pharmacogenomics Journal 2004 4 5 291 306 (Pubitemid 39345133)
20. Kaiser R., Hofer A., Grapengiesser A., Gasser T., Kupsch A., Roots I., Brockmller J., L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism Neurology 2003 60 11 1750 1755 (Pubitemid 36737068)
21. Oliveri R. L., Annesi G., Zappia M., Civitelli D., Montesanti R., Branca D., Nicoletti G., Spadafora P., Pasqua A. A., Cittadella R., Andreoli V., Gambardella A., Aguglia U., Quattrone A., Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD Neurology 1999 53 7 1425 1430 (Pubitemid 29491932)
22. Koller W. C., Tse W., Olanow, Hauser, Jenner, Obeso, LeWitt, Stocchi, Unmet medical needs in Parkinson's disease Neurology 2004 62 supplement 1 S1 S8
23. Fahn S., The spectrum of levodopa-induced dyskinesias Annals of Neurology 2000 47 supplement 1 S2 S11
24. Globe L. I., Young-onset Parkinson's disease: a clinical review Neurology 1991 41 168 173
25. Boyce S., Clarke C. E., Luquin R., Peggs D., Robertson R. G., Mitchell I. J., Sambrook M. A., Crossman A. R., Induction of chorea and dystonia in parkinsonian primates Movement Disorders 1990 5 1 3 7 (Pubitemid 20110859)
26. Durif F., Treating and preventing levodopa-induced dyskinesias: current and future strategies Drugs and Aging 1999 14 5 337 345 (Pubitemid 29213774)
27. Boraud T., Bezard E., Bioulac B., Gross C. E., Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey Brain 2001 124 546 557 (Pubitemid 32221322)
28. Jankovic J., Rajput A. H., McDermott M. P., Perl D. P., The evolution of diagnosis in early Parkinson disease Archives of Neurology 2000 57 3 369 372 (Pubitemid 30140525)
29. Schrag A., Ben-Shlomo Y., Brown R., Marsden C. D., Quinn N., Young-onset Parkinson's disease revisitedclinical features, natural history, and mortality Movement Disorders 1998 13 6 885 894 (Pubitemid 28517664)
30. Sossi V., De La Fuente-Fernndez R., Schulzer M., Adams J., Stoessl J., Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications Brain 2006 129 1050 1058
31. Di Monte D. A., McCormack A., Petzinger G., Janson A. M., Quik M., Langston W. J., Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model Movement Disorders 2000 15 3 459 466 (Pubitemid 30333216)
32. Linazasoro G., New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity Trends in Pharmacological Sciences 2005 26 8 391 397 (Pubitemid 41039214)
33. Linazasoro G., Van Blercom N., Bergaretxe A., Fernndez Manchola I., Laborda E., Ruiz Ortega J. A., Levodopa-induced dyskinesias in parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study Clinical Neuropharmacology 2009 32 6 326 329
34. Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J., Sibley D. R., D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 1990 250 4986 1429 1432 (Pubitemid 120031867)
35. Nash J. E., Brotchie J. M., A common signaling pathway for striatal NMDA and adenosine A(2a) receptors: implications for the treatment of Parkinson's disease Journal of Neuroscience 2000 20 20 7782 7789
36. Santini E., Valjent E., Fisone G., Parkinson's disease: levodopa-induced dyskinesia and signal transduction FEBS Journal 2008 275 7 1392 1399 (Pubitemid 351388785)
37. Boyce S., Rupniak N. M. J., Steventon M. J., Iversen S. D., Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys Clinical Neuropharmacology 1990 13 5 448 458 (Pubitemid 20285578)
38. Kumar A., Mann S., Sossi V., Ruth T. J., Stoessl A. J., Schulzer M., Lee C. S., [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease Brain 2003 126 12 2648 2655 (Pubitemid 37463084)
39. de la Fuente-Fernndez R., Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations Clinical Neuropharmacology 1999 22 4 216 219
40. Fleckenstein A. E., Volz T. J., Hanson G. R., Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications Neuropharmacology 2009 56 supplement 1 133 138
41. Dreyer J. K., Herrik K. F., Berg R. W., Hounsgaard J. D., Influence of phasic and tonic dopamine release on receptor activation Journal of Neuroscience 2010 30 42 14273 14283
42. Obeso J. A., Olanow C. W., Nutt J. G., Levodopa motor complications in Parkinson's disease Trends in Neurosciences 2000 23 10 S2 S7
43. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., DeLong M. R., Olanow C. W., Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model Annals of Neurology 2000 47 supplement 1 S22 S34
44. Bjrklund T., Carlsson T., Cederfjll E. A., Carta M., Kirik D., Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease Brain 2010 133 496 511
45. Mouradian M. M., Juncos J. L., Fabbrini G., Chase T. N., Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies Annals of Neurology 1987 22 4 475 479 (Pubitemid 17164770)
46. Stocchi F., The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease Parkinsonism and Related Disorders 2009 15 supplement 3 S68 S71
47. Bezard E., Brotchie J. M., Gross C. E., Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nature Reviews Neuroscience 2001 2 8 577 588 (Pubitemid 33679831)
48. Cenci M. A., Lee C. S., Bjrklund A., L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA European Journal of Neuroscience 1998 10 8 2694 2706 (Pubitemid 28362576)
49. Fiorentini C., Rizzetti M. C., Busi C., Bontempi S., Collo G., Spano P., Missale C., Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat Molecular Pharmacology 2006 69 3 805 812 (Pubitemid 43363855)
50. Missale C., Nash S. R., Robinson S. W., Jaber M., Caron M. G., Dopamine receptors: from structure to function Physiological Reviews 1998 78 1 189 225 (Pubitemid 28070979)
51. Le Moine C., Bloch B., D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum Journal of Comparative Neurology 1995 355 3 418 426
52. Morelli M., DiChiara G., Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning European Journal of Pharmacology 1987 141 1 101 107 (Pubitemid 17148197)
53. Xiao D., Bastia E., Xu Y. H., Benn C. L., Cha J. H. J., Peterson T. S., Chen J. F., Schwarzschild M. A., Forebrain adenosine A 2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice Journal of Neuroscience 2006 26 52 13548 13555 (Pubitemid 46026487)
54. Smith L. A., Jackson M. J., Johnston L., Kuoppamaki M., Rose S., Al-Barghouthy G., Del Signore S., Jenner P., Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates Clinical Neuropharmacology 2006 29 3 112 125 (Pubitemid 44503888)
55. Jackson M. J., Smith L. A., Al-Barghouthy G., Rose S., Jenner P., Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets Experimental Neurology 2007 204 1 162 170 (Pubitemid 46330268)
56. Cotzias G. C., Papavasiliou P. S., Tolosa E. S., Treatment of Parkinson's disease with aporphrines. Possible role of growth hormone The New England Journal of Medicine 1976 294 11 567 572
57. Brodsky M. A., Park B. S., Nutt J. G., Effects of a dopamine agonist on the pharmacodynamics of levodopa in parkinson disease Archives of Neurology 2010 67 1 27 32
58. Stockwell K. A., Scheller D. K. A., Smith L. A., Rose S., Iravani M. M., Jackson M. J., Jenner P., Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets Experimental Neurology 2010 221 1 79 85
59. Linazasoro G., Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial Archives of Neurology 2007 64 1 137 140 (Pubitemid 46072438)
60. Olanow C. W., Obeso J. A., Preventing levodopa-induced dyskinesias Annals of Neurology 2000 47 4 S167 S178
61. Metman L. V., Konitsiotis S., Chase T. N., Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what Movement Disorders 2000 15 1 3 8 (Pubitemid 30037981)
62. Constantinescu R., Romer M., McDermott M. P., Kamp C., Kieburtz K., Impact of pramipexole on the onset of levodopa-related dyskinesias Movement Disorders 2007 22 9 1317 1319 (Pubitemid 47325041)
63. Pearce R. K. B., Banerji T., Jenner P., Marsden C. D., De novo administration of ropinirole and bromocriptine induces less dyskinesia than levodopa in the MPTP-treated marmoset Movement Disorders 1998 13 2 234 241 (Pubitemid 28127797)
64. Maratos E. C., Jackson M. J., Pearce R. K. B., Jenner P., Antiparkinsonian activity and dyskinesia risk of ropinirole and levodopa combination therapy in drug nave MPTP-lesioned common marmosets (Callithrix jacchus) Movement Disorders 2001 16 4 631 641 (Pubitemid 36040842)
65. Blanchet P. J., Calon F., Morissette M., Goulet M., Grondin R., Lévesque D., Bédard P. J., Di Paolo T., Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model Advances in Neurology 2001 86 337 344
66. Hely M. A., Morris J. G. L., Reid W. G. J., O'Sullivan D. J., Williamson P. M., Rail D., Broe G. A., Margrie S., The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa Journal of Neurology Neurosurgery and Psychiatry 1994 57 8 903 910 (Pubitemid 24251051)
67. Lees A. J., Katzenschlager R., Head J., Ben-Shlomo Y., Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial Neurology 2001 57 9 1687 1694 (Pubitemid 33055490)
68. Oertel W. H., Wolters E., Sampaio C., Gimenez-Roldan S., Bergamasco B., Dujardin M., Grosset D. G., Arnold G., Leenders K. L., Hundemer H. P., Lled A., Wood A., Frewer P., Schwarz J., Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study Movement Disorders 2006 21 3 343 353
69. Obeso J. A., Rodriguez-Oroz M. C., Zamarbide I., Schapira A. H. V., Olanow C. W., Clinical features, pathophysiology, and management of motor complications in Parkinson's disease Principles of Treatment in Parkinson's Disease 2005 Philadelphia, Pa, USA Butterworth Heinemann Elsevier 99 112
70. Nirenberg M. J., Fahn S., Schapira A. H. V., Olanow C. W., The role of levodopa and catechol-o-methyltransferase inhibitors Principles of Treatment in Parkinson's Disease 2005 Philadelphia, Pa, USA Butterworth Heinemann Elsevier 3 16
71. Olanow C. W., Fahn S., Muenter M., Klawans H., Hurtig H., Stern M., Shoulson I., Kurlan R., Grimes J. D., Jankovic J., Hoehn M., Markham C. H., Duvoisin R., Reinmuth O., Leonard H. A., Ahlskog E., Feldman R., Hershey L., Yahr M. D., A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease Movement Disorders 1994 9 1 40 47 (Pubitemid 24022613)
72. Parkinson Study Group, A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study Clinical Neuropharmacology 2000 23 1 34 44
73. Parkinson Study Group, Pramipexole versus levodopa as initial treatment for Parkinson disease: a randomized controlled trial The Journal of the American Medical Association 2000 284 15 1931 1938
74. Parkinson Study Group CALM Cohort Investigators, Long-term effect of initiating pramipexole versus levodopa in early Parkinson disease Archives of Neurology 2009 66 563 570
75. Hauser R. A., Rascol O., Korczyn A. D., Stoessl A. J., Watts R. L., Poewe W., De Deyn P. P., Lang A. E., Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa Movement Disorders 2007 22 16 2409 2417 (Pubitemid 351155989)
76. Watts R. L., Lyons K. E., Pahwa R., Sethi K., Stern M., Hauser R. A., Olanow W., Gray A. M., Adams B., Earl N. L., Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease Movement Disorders 2010 25 7 858 866
77. Colzi A., Turner K., Lees A. J., Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease Journal of Neurology Neurosurgery and Psychiatry 1998 64 5 573 576 (Pubitemid 28204140)
78. Manson A. J., Turner K., Lees A. J., Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients Movement Disorders 2002 17 6 1235 1241 (Pubitemid 36041337)
79. Poewe W. H., Rascol O., Quinn N., Tolosa E., Oertel W. H., Martignoni E., Rupp M., Boroojerdi B., Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial The Lancet Neurology 2007 6 6 513 520 (Pubitemid 46734759)
80. Pahwa R., Stacy M. A., Elmer L. W., Isaacson S. H., Ropinirole 24-hour prolonged release provides efficacy as early as week 2 when used as adjunctive therapy to levodopa in patients with advanced Parkinson's disease Movement Disorders 2006 21 supplement 15 S595
81. Pahwa R., Stacy M. A., Factor S. A., Lyons K. E., Stocchi F., Hersh B. P., Elmer L. W., Truong D. D., Earl N. L., Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease Neurology 2007 68 14 1108 1115 (Pubitemid 46559844)
82. Sethi K. D., Hauser R. A., Earl N. L., Ropinirole 24-hour prolonged release improves disease-specific and global symptoms when used as adjunctive therapy to levodopa in patients with advanced Parkinson's disease Movement Disorders 2006 21 supplement 15 S570
83. Sethi K. D., Stocchi F., Giorgi L., Ropinirole 24-hour prolonged release in advanced Parkinson's disease: relationship between treatment response and disease severity Movement Disorders 2007 22 supplement 16 S92
84. Stacy M. A., Pahwa R., Earl N. L., Ropinirole 24-hour prolonged release reduces off time and the dose of levodopa needed when used as adjunctive therapy in patients with advanced Parkinson's disease Movement Disorders 2006 21 supplement 15 S596
85. Stocchi F., Hersh B. P., Earl N. L., Scott B. L., Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson's disease Movement Disorders 2006 21 supplement 15 S572
86. Stocchi F., Stover N. P., Giorgi L., Ropinirole 24-hour prolonged release as adjunct to levodopa in patients with advanced Parkinson's diseaseefficacy according to baseline depression score Movement Disorders 2007 22 supplement 16 S90
87. Mller J. C., Oertel W. H., Kster J., Pezzoli G., Provinciali L., Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial Movement Disorders 2005 20 5 602 610 (Pubitemid 40862259)
88. Knig G., Pogarell O., Mller J. C., Delf M., Oertel W. H., Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease Clinical Neuropharmacology 1999 22 5 301 305 (Pubitemid 29506403)
89. Wong K. S., Lu C. S., Shan D. E., Yang C. C., Tsoi T. H., Mok V., Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease Journal of the Neurological Sciences 2003 216 1 81 87 (Pubitemid 37371869)
90. Musch B., Bonura L., Cabergoline once a day as adjunctive therapy to levodopa in Parkinson's disease Movement Disorders 2000 15 supplement 3
91. Pinter M. M., Pogarell O., Oertel W. H., Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study Journal of Neurology Neurosurgery and Psychiatry 1999 66 4 436 441 (Pubitemid 29145676)
92. Wermuth L., A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease European Journal of Neurology 1998 5 3 235 242 (Pubitemid 28256611)
93. Lieberman A., Ranhosky A., Korts D., Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study Neurology 1997 49 1 162 168 (Pubitemid 27328697)
94. Weiner W. J., Factor S. A., Jankovic J., Hauser R. A., Tetrud J. W., Waters C. H., Shulman L. M., Glassman P. M., Beck B., Paume D., Doyle C., The long-term safety and efficacy of pramipexole in advanced Parkinson's disease Parkinsonism and Related Disorders 2001 7 2 115 120 (Pubitemid 32184565)
95. Guttman M., Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease Neurology 1997 49 4 1060 1065 (Pubitemid 27456088)
96. Kreider M., Knox S., Gardiner D., Wheadon D., A multicenter double-blind study of ropinirole as an adjunct to levodopa in Parkinson's disease Neurology 1996 46: A475
97. Lieberman A., Olanow C. W., Sethi K., Swanson P., Waters C. H., Fahn S., Hurtig H., Yahr M., A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease Neurology 1998 51 4 1057 1062 (Pubitemid 28473400)
98. Rascol O., Lees A. J., Senard J. M., Pirtosek Z., Brefel C., Montastruc J. L., Fuell D., A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients Advances in Neurology 1996 69 531 534
99. Rascol O., Lees A. J., Senard J. M., Pirtosek Z., Montastruc J. L., Fuell D., Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease Clinical Neuropharmacology 1996 19 3 234 245 (Pubitemid 26152339)
100. Steiger M. J., El-Debas T., Anderson T., Findley L. J., Marsden C. D., Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations Journal of Neurology 1996 243 1 68 72 (Pubitemid 126423446)
101. Hutton J. T., Koller W. C., Ahlskog J. E., Pahwa R., Hurtig H. I., Stern M. B., Hiner B. C., Lieberman A., Pfeiffer R. F., Rodnitzky R. L., Waters C. H., Muenter M. D., Adler C. H., Morris J. L., Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease Neurology 1996 46 4 1062 1065 (Pubitemid 26134653)
102. Lieberman A. N., Hutton J. T., Levodopa sparing effect of cabergoline compared to placebo in patients affected by motor fluctuations, under levodopa therapy Movement Disorders 1996 11 supplement 1 269
103. Schoenfelder J., Simons J., Souder D. E., Bianchine J., A placebo-controlled study of the safety and efficacy of cabergoline in the treatment of Parkinson's disease Functional Capacity Evaluation Reports 1993 21336/731i. Clinical Reference 42
104. Olanow C. W., Fahn S., Muenter M., Klawans H., Hurtig H., Stern M., Shoulson I., Kurlan R., Grimes J. D., Jankovic J., Hoehn M., Markham C. H., Duvoisin R., Reinmuth O., Leonard H. A., Ahlskog E., Feldman R., Hershey L., Yahr M. D., A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease Movement Disorders 1994 9 1 40 47 (Pubitemid 24022613)
105. Temlett J. A., Ming A., Saling M., Fritz V. U., Blumenfeld A., Bilchik T. R., Becker A. L., Fourie P. B., Reef H. E., Adjunctive therapy with bromocriptine in Parkinson's disease South African Medical Journal 1990 78 11 680 685
106. Toyokura Y., Mizuno Y., Kase M., Effects of bromocriptine on Parkinsonism. A nation-wide collaborative double-blind study Acta Neurologica Scandinavica 1985 72 2 157 170 (Pubitemid 16253311)
107. Schneider E., Fischer P. A., Bromocriptine in the treatment of progressive stages of Parkinson's disease Deutsche Medizinische Wochenschrift 1982 107 5 175 179 (Pubitemid 12162082)
108. Jansen E. N. H., Bromocryptine in levodopa response-losing parkinsonism. A double blind study European Neurology 1978 17 2 92 99 (Pubitemid 8276019)
109. Stocchi F., Ruggieri S., Vacca L., Olanow C. W., Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease Brain 2002 125 9 2058 2066
110. Rinne U. K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J. F., Montastruc J. L., Marsden C. D., Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial Drugs 1998 55 supplement 1 23 30 (Pubitemid 28051035)
111. Clarke C. E., Deane K. D., Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease Cochrane Database of Systematic Reviews 2001 1
112. Stowe R., Ives N., Clarke C. E., Deane K., van Hilten, Wheatley K., Gray R., Handley K., Furmston A., Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications Cochrane Database of Systematic Reviews 2010 7 CD007166
113. Jankovic J., Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Movement Disorders 2005 20 supplement 11 S11 S16
114. Metman L. V., Del Dotto P., van den Munchkof P., Fang J., Mouradian M. M., Chase T. N., Amantadine as treatment for dyskinesias in Parkinson's disease Neurology 1998 50 5 1323 1326 (Pubitemid 28240346)
115. Lugging E., Wenning G. K., Bosch S., Beneficial effects of amantadine on levodopa-induced dyskinesias in Parkinson's disease Movement Disorders 2000 15 873 878
116. Snow B. J., Macdonald L., Mcauley D., Wallis W., The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study Clinical Neuropharmacology 2000 23 2 82 85 (Pubitemid 30212217)
117. Crosby N. J., Deane K. H., Clarke C. E., Amantadine for dyskinesia in Parkinson's disease Cochrane Database of Systematic Reviews 2003 2 CD003467
118. Durif F., Debilly B., Galitzky M., Morand D., Viallet F., Borg M., Thobois S., Broussolle E., Rascol O., Clozapine improves dyskinesias in Parkinson disease A double-blind, placebo-controlled study Neurology 2004 62 3 381 388 (Pubitemid 38200847)
119. Pierelli F., Adipietro A., Soldati G., Fattapposta F., Pozzessere G., Scoppetta C., Low dosage clozapine effects on levodopa induced dyskinesias in parkinsonian patients Acta Neurologica Scandinavica 1998 97 5 295 299 (Pubitemid 28191920)
120. Anderson V. C., Burchiel K. J., Hogarth P., Favre J., Hammerstad J. P., Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease Archives of Neurology 2005 62 4 554 560 (Pubitemid 40489885)
121. Ford B., Winfield L., Pullman S. L., Frucht S. J., Du Y., Greene P., Cheringal J. H., Yu Q., Cote L. J., Fahn S., McKhann G. M., Goodman R. R., Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up Journal of Neurology, Neurosurgery and Psychiatry 2004 75 9 1255 1259 (Pubitemid 39141328)
122. stergaard K., Sunde N., Dupont E., Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations Movement Disorders 2002 17 4 693 700 (Pubitemid 41295008)
123. Moro E., Scerrati M., Romito L. M. A., Roselli R., Tonali P., Albanese A., Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease Neurology 1999 53 1 85 90 (Pubitemid 29329653)
124. Vingerhoets F. J. G., Villemure J. G., Temperli P., Pollo C., Pralong E., Ghika J., Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up Neurology 2002 58 3 396 401 (Pubitemid 34150913)